DelveInsight’s, “Chronic Kidney Disease Competitive Landscape 2023” report provides comprehensive insights about 75+ Chronic Kidney Disease Companies and 95+ drugs in the Chronic Kidney Disease Competitive landscape. It covers the Chronic Kidney Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Chronic Kidney Disease Competitive Landscape Report

• DelveInsight’s Chronic Kidney Disease report depicts a robust space with 75+ Chronic Kidney Disease companies working to develop 95+ therapies for Chronic Kidney Disease treatment.
• The leading Chronic Kidney Disease Companies working in the market include Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, KBP Biosciences, AstraZeneca, Allena Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, CinCor Pharma, Galapagos NV, Sentien Biotechnologies, Inc., Regeneron Pharmaceuticals, UnicoCell Biomed, OccuRx, Pharmicell, Lisata Therapeutics, Unicycive Therapeutics, Senda Biosciences, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, GNI Group, Algomedix, Maze Therapeutics, Chinook Therapeutics, Angion Biomedica Corp, Arch Biopartners, Scohia Pharma, Algernon Pharmaceuticals, TICEBA GmbH, and others.
• Promising Chronic Kidney Disease Therapies in the various stages of development include Roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, rHuEPO, AST-120, Epoetin Alfa, and others.
• December 2023: AstraZeneca announced a study of Phase 3 clinical trials for Dapagliflozin and Zibotentan/Dapagliflozin. This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria.
• March 2023, POXEL SA, announced the publication of preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. For the first time, POXEL SA showed beneficial effects of a direct and selective AMPK activator in preclinical ADPKD models from three species mouse, human, and dog. These results confirm the potential utility of AMPK activation for this disease and support the development of PXL770 in a Phase 2 clinical program for ADPKD.
• February 2023, AstraZeneca announced the successful completion of the acquisition of CinCor Pharma, Inc. The acquisition bolsters AstraZeneca’s cardiorenal pipeline by adding baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension, to its cardiorenal portfolio.
• January 2023, The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company announced

 

Request a sample and discover the recent advances in Chronic Kidney Disease Drugs @ Chronic Kidney Disease Competitive Landscape Report

 

The Chronic Kidney Disease report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the Chronic Kidney Disease report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

 

Chronic Kidney Disease Overview

Chronic Kidney Disease is a condition in which kidneys are damaged and cannot filter blood. As a result, extra fluid and waste from the blood remain in the body, potentially leading to various health issues like heart disease and stroke. Chronic Kidney Disease has various levels of seriousness.

 

Find out more about Chronic Kidney Disease Analytical Perspective: In-depth Commercial Assessment @ Chronic Kidney Disease Collaboration Analysis by Companies

 

Chronic Kidney Disease Companies and Therapies

• AstraZeneca: Forxiga
• Otsuka Pharmaceutical Co., Ltd.: JYNARQUE
• Boehringer Ingelheim: Empagliflozin
• KBP Biosciences: KBP-5074
• Bayer: Runcaciguat
• Regulus Therapeutics: RGLS8429

 

Chronic Kidney Disease Competitive Landscape

The Chronic Kidney Disease report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

 

Chronic Kidney Disease Report Assessment

• Company Analysis
• Chronic Kidney Disease Therapeutic Assessment
• Chronic Kidney Disease Pipeline Assessment
• Inactive Chronic Kidney Disease Drugs Assessment
• Chronic Kidney Disease Unmet Needs

 

Learn more about the emerging Chronic Kidney Disease Competitive Landscape @ Chronic Kidney Disease Market Drivers and Barriers, Unmet Needs

 

Scope of the Chronic Kidney Disease Report

• Coverage- Global
• Chronic Kidney Disease Companies- Boehringer Ingelheim, Eli Lilly and Company, Reata Pharmaceuticals, Novo Nordisk, KBP Biosciences, AstraZeneca, Allena Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, CinCor Pharma, Galapagos NV, Sentien Biotechnologies, Inc., Regeneron Pharmaceuticals, UnicoCell Biomed, OccuRx, Pharmicell, Lisata Therapeutics, Unicycive Therapeutics, Senda Biosciences, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, GNI Group, Algomedix, Maze Therapeutics, Chinook Therapeutics, Angion Biomedica Corp, Arch Biopartners, Scohia Pharma, Algernon Pharmaceuticals, TICEBA GmbH, and others.
• Chronic Kidney Disease Therapies- Roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, rHuEPO, AST-120, Epoetin Alfa, and others.
• Chronic Kidney Disease Therapeutics Assessment- Product Type, Stage and Product Type, Route of Administration, Stage and Route of Administration, Molecule Type, Stage and Molecule Type

 

Dive deep into rich insights for new drugs for Chronic Kidney Disease Product Developmental Activities, Visit @ Chronic Kidney Disease Research and Development Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. Chronic Kidney Disease: Overview
4. Chronic Kidney Disease -Analytical Perspective: In-depth Commercial Assessment
5. Chronic Kidney Disease Competitive Landscape
6. Chronic Kidney Disease Therapeutic Assessment
7. Chronic Kidney Disease: Company and Product Profiles (Marketed Therapies)
8. AstraZeneca
9. Forxiga
10. Chronic Kidney Disease: Company and Product Profiles (Pipeline Therapies)
11. Late Stage Products (Phase III)
12. KBP Biosciences
13. KBP-5074
14. Drug profiles in the detailed report…..
15. Mid Stage Products (Phase II)
16. Bayer
17. Runcaciguat
18. Drug profiles in the detailed report…..
19. Early Stage Products (Phase I)
20. Regulus Therapeutics
21. RGLS8429
22. Drug profiles in the detailed report…..
23. Preclinical and Discovery Stage Products
24. Maze Therapeutics
25. APOL1 Programme
26. Drug profiles in the detailed report…..
27. Inactive Products
28. Chronic Kidney Disease Unmet needs
29. Chronic Kidney Disease Market drivers and barriers
30. Appendix

 

For further information on the Chronic Kidney Disease Report @ Chronic Kidney Disease Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services